These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27556957)
21. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169 [TBL] [Abstract][Full Text] [Related]
22. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Nowecki ZI; Rutkowski P; Michej W Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535 [TBL] [Abstract][Full Text] [Related]
23. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331 [TBL] [Abstract][Full Text] [Related]
24. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089 [TBL] [Abstract][Full Text] [Related]
25. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846 [TBL] [Abstract][Full Text] [Related]
26. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Hughes TM; A'Hern RP; Thomas JM Br J Surg; 2000 Jul; 87(7):892-901. PubMed ID: 10931025 [TBL] [Abstract][Full Text] [Related]
27. Sentinel lymph node dissection for primary cutaneous melanoma: a community hospital's initial experience. Habib FA; Lodish ME; Mittal VK; Young SC Am Surg; 2000 Mar; 66(3):291-5. PubMed ID: 10759202 [TBL] [Abstract][Full Text] [Related]
28. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Satzger I; Meier A; Hoy L; Völker B; Kapp A; Hauschild A; Gutzmer R Ann Surg Oncol; 2011 Feb; 18(2):514-20. PubMed ID: 20839060 [TBL] [Abstract][Full Text] [Related]
30. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589 [TBL] [Abstract][Full Text] [Related]
31. Sentinel lymphadenectomy for staging patients with intermediate-level melanoma. Smart KR; Cahoon BW; Dale PS Am Surg; 2000 Mar; 66(3):280-3. PubMed ID: 10759200 [TBL] [Abstract][Full Text] [Related]
32. Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. Oude Ophuis CM; van Akkooi AC; Rutkowski P; Powell WE; Robert C; Testori A; van Leeuwen BL; Siegel P; Eggermont AM; Verhoef C; Grünhagen DJ Br J Surg; 2017 May; 104(6):726-733. PubMed ID: 28218385 [TBL] [Abstract][Full Text] [Related]
33. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814 [TBL] [Abstract][Full Text] [Related]
34. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients. Fujisawa Y; Otsuka F; Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797 [TBL] [Abstract][Full Text] [Related]
35. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421 [TBL] [Abstract][Full Text] [Related]
36. Survival impact of immediate complete lymph node dissection for Chinese acral and cutaneous melanoma with micrometastasis in sentinel nodes: a retrospective study. Zhong J; Zou Z; Hu T; Sun W; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y Clin Exp Med; 2023 Nov; 23(7):4003-4010. PubMed ID: 37300655 [TBL] [Abstract][Full Text] [Related]
37. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Gutzmer R; Al Ghazal M; Geerlings H; Kapp A Br J Dermatol; 2005 Dec; 153(6):1137-41. PubMed ID: 16307648 [TBL] [Abstract][Full Text] [Related]
39. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. van der Ploeg AP; van Akkooi AC; Schmitz PI; Koljenovic S; Verhoef C; Eggermont AM Eur J Cancer; 2010 Sep; 46(13):2414-21. PubMed ID: 20621467 [TBL] [Abstract][Full Text] [Related]
40. Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. Senchenkov A; Barnes SA; Moran SL J Surg Oncol; 2007 Mar; 95(3):229-34. PubMed ID: 17323336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]